SCMP Share Price

Open 10.65 Change Price %
High 10.65 1 Day -0.15 -1.41
Low 10.35 1 Week 0.15 1.45
Close 10.50 1 Month 0.85 8.81
Volume 438577 1 Year -1.36 -11.47
52 Week High 17.55
52 Week Low 9.30
SCMP Important Levels
Resistance 2 10.78
Resistance 1 10.66
Pivot 10.50
Support 1 10.34
Support 2 10.22
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
ASTI 0.00 0.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
DCTH 0.02 -33.33%
More..
NASDAQ USA Top Gainers Stocks
HMNY 3.81 55.51%
LOCM 0.09 50.00%
GSOL 17.88 49.00%
OPXAW 0.04 33.33%
WRES 0.09 28.57%
CGEI 0.28 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
BEBE 4.67 23.22%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
HAUP 0.07 -58.82%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP)

SCMP Technical Analysis 2
As on 23rd May 2017 SCMP Share Price closed @ 10.50 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 12.04 & Buy for SHORT-TERM with Stoploss of 10.44 we also expect STOCK to react on Following IMPORTANT LEVELS.
SCMP Target for May
1st Target up-side 11.08
2nd Target up-side 11.73
3rd Target up-side 12.38
1st Target down-side 9.22
2nd Target down-side 8.57
3rd Target down-side 7.92
SCMP Other Details
Segment EQ
Market Capital 208269664.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.sucampo.com
SCMP Address
SCMP
4520 East-West Highway
3rd Floor
Bethesda, MD 20814
United States
Phone: 301-961-3400
Fax: 301-961-3440
SCMP Latest News
Interactive Technical Analysis Chart Sucampo Pharmaceuticals, Inc. ( SCMP NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Sucampo Pharmaceuticals, Inc.
SCMP Business Profile
Sucampo Pharmaceuticals, Inc. is a global biopharmaceutical company focused on research, discovery, development and commercialization of drugs based on ion channel activators known as prostones. The Company�s prostone-based compounds target the ClC-2 and big potassium (BK), ion channels. It is focused on developing prostones to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and is also considering other therapeutic applications of its drug technology. The Company�s products include AMITIZA (lubiprostone) and RESCULA (unoprostone isopropyl). AMITIZA is marketed in the United States for three gastrointestinal indications: chronic idiopathic constipation (CIC), in adults, irritable bowel syndrome with constipation (IBS-C), in adult women, and opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. RESCULA is a BK channel activator and has a different mechanism of action than other IOP lowering agents on the market.